10x Genomics (TXG) 10-Q 5 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		93,925,480
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		19,446,465

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 312,487	$ 587,447
Marketable securities	226,836	0
Restricted cash	27	1,028
Accounts receivable, net	76,526	85,254
Inventory	63,697	59,966
Prepaid expenses and other current assets	17,762	13,896
Total current assets	697,335	747,591
Property and equipment, net	190,200	169,492
Restricted cash	7,598	7,598
Operating lease right-of-use assets	75,680	60,918
Goodwill	4,511	4,511
Intangible assets, net	24,764	25,397
Other noncurrent assets	3,163	3,319
Total assets	1,003,251	1,018,826
Current liabilities:
Accounts payable	18,956	17,351
Accrued compensation and related benefits	18,324	31,626
Accrued expenses and other current liabilities	44,095	50,909
Deferred revenue	5,434	5,340
Operating lease liabilities	7,637	5,131
Total current liabilities	94,446	110,357
Accrued license fee, noncurrent	0	5,814
Operating lease liabilities, noncurrent	93,538	76,847
Other noncurrent liabilities	8,582	8,240
Total liabilities	196,566	201,258
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	1,714,860	1,680,865
Accumulated deficit	(905,734)	(863,321)
Accumulated other comprehensive income (loss)	(2,443)	22
Total stockholders’ equity	806,685	817,568
Total liabilities and stockholders’ equity	$ 1,003,251	$ 1,018,826

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 114,496	$ 105,821
Cost of revenue	25,478	17,060
Gross profit	89,018	88,761
Operating expenses:
Research and development	64,078	41,883
Selling, general and administrative	66,675	56,904
Accrued contingent liabilities	0	190
Total operating expenses	130,753	98,977
Loss from operations	(41,735)	(10,216)
Other income (expense):
Interest income	569	50
Interest expense	(128)	(221)
Other expense, net	(400)	(729)
Total other income (expense)	41	(900)
Loss before provision for income taxes	(41,694)	(11,116)
Provision for income taxes	719	435
Net loss	$ (42,413)	$ (11,551)
Net loss per share, basic (in dollars per share)	$ (0.38)	$ (0.11)
Net loss per share, diluted (in dollars per share)	$ (0.38)	$ (0.11)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	112,966,196	108,714,027
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	112,966,196	108,714,027

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (42,413)	$ (11,551)
Other comprehensive income (loss), net of tax:
Unrealized losses on available-for-sale marketable securities	(2,403)	0
Foreign currency translation adjustment	(62)	98
Other comprehensive income (loss), net of tax	(2,465)	98
Comprehensive loss	$ (44,878)	$ (11,453)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Common Class A	Common Class ACommon Stock	Common Class AAdditional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	$ 739,072	$ 2	$ 1,544,218	$ (805,098)	$ (50)
Issuance of Class A common stock related to equity awards (in shares)							1,102,618
Issuance of Class A common stock related to equity awards						$ 8,546		$ 8,546
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	16,253		16,253
Net loss	(11,551)			(11,551)
Other comprehensive loss	98				98
Ending balance (in shares) at Mar. 31, 2021		109,588,527
Ending balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Beginning balance (in shares) at Dec. 31, 2021		112,514,977
Beginning balance at Dec. 31, 2021	817,568	$ 2	1,680,865	(863,321)	22
Issuance of Class A common stock related to equity awards (in shares)							761,373
Issuance of Class A common stock related to equity awards						$ 7,826		$ 7,826
Vesting of shares subject to repurchase, including early exercised options	32		32
Stock-based compensation	26,137		26,137
Net loss	(42,413)			(42,413)
Other comprehensive loss	(2,465)				(2,465)
Ending balance (in shares) at Mar. 31, 2022		113,276,350
Ending balance at Mar. 31, 2022	$ 806,685	$ 2	$ 1,714,860	$ (905,734)	$ (2,443)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net loss	$ (42,413)	$ (11,551)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,191	4,752
Stock-based compensation expense	26,047	16,176
Loss on disposal of property and equipment	0	30
Amortization of premium and accretion of discount on marketable securities, net	183	0
Amortization of right-of-use assets	1,784	1,716
Changes in operating assets and liabilities:
Accounts receivable	8,728	(6,189)
Inventory	(3,736)	(8,614)
Prepaid expenses and other current assets	(3,873)	(1,584)
Other noncurrent assets	157	165
Accounts payable	2,875	10,885
Accrued compensation and other related benefits	(13,283)	1,302
Deferred revenue	230	348
Accrued contingent liabilities	0	676
Accrued expenses and other current liabilities	(3,541)	(7,232)
Operating lease liability	(357)	(1,424)
Other noncurrent liabilities	206	(3,538)
Net cash used in operating activities	(20,802)	(4,082)
Investing activities:
Acquisition of business, net of cash acquired	0	(5,451)
Purchases of property and equipment	(28,136)	(38,865)
Purchase of marketable securities	(242,329)	0
Proceeds from sales and maturities of marketable securities	12,907	0
Net cash used in investing activities	(257,558)	(44,316)
Financing activities:
Payments on financing arrangement	(5,409)	(5,028)
Issuance of common stock from exercise of stock options	7,826	8,546
Net cash provided by financing activities	2,417	3,518
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	(18)	193
Net decrease in cash, cash equivalents, and restricted cash	(275,961)	(44,687)
Cash, cash equivalents, and restricted cash at beginning of period	596,073	688,644
Cash, cash equivalents, and restricted cash at end of period	320,112	643,957
Supplemental disclosures of cash flow information:
Cash paid for interest	841	1,222
Cash paid for taxes	2,900	6,822
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	15,023	2,816
Right-of-use assets obtained in exchange for new operating lease liabilities	16,562	11,237
Contingent consideration payable from business acquisition	$ 1,500	$ 1,500

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012 and is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium Controller, Chromium Connect and Chromium X Series instruments, which the Company refers to as “instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for our Visium solution, which does not require a 10x Genomics instrument, and our Chromium solution, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe and North America. Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2021 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K filed with the SEC on February 18, 2022 (our "Annual Report").

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies There were no material changes in our significant accounting policies during the three months ended March 31, 2022, except as set forth below. See Note 2 – Summary of Significant Accounting Policies to the consolidated financial statements included in our Annual Report, for information regarding our significant accounting policies. Marketable Securities The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities, within current assets on the balance sheet. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in "Accumulated other comprehensive income (loss)", a component of stockholders’ equity, net of tax. Realized gains (losses) on the sale of marketable securities are determined using the specific-identification method and recorded in "Other expense, net" in the Consolidated Statements of Operations. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in “Other expense, net”, and unrealized losses not related to credit losses are recognized in “Accumulated other comprehensive income (loss)”. There are no allowances for credit losses for the periods presented. As of March 31, 2022, the gross unrealized losses on available-for-sale securities are related to market interest rate changes and not attributable to credit. Fair Value of Financial Instruments Cash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy. Assets recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 - Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s financial instruments consist of Level 1, Level 2 and Level 3 assets. Where quoted prices are available in an active market, securities are classified as Level 1. Money market funds are classified as Level 1. Level 2 assets consist primarily of corporate bonds, asset backed securities, commercial paper, U.S. Government Treasury and agency securities, and debt securities in government-sponsored entities based upon quoted market prices for similar movements in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to, benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis.

Other Financial Statement Infor

Other Financial Statement Information	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Available-for-sale Securities Available-for-sale securities at March 31, 2022 consisted of the following (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Fair Value Measurement Cash equivalents: Money market funds $ 254,366 $ — $ — $ 254,366 Level 1 Marketable securities: Corporate debt securities 158,165 10 (1,817) 156,358 Level 2 Government debt securities 54,102 — (527) 53,575 Level 2 Asset-backed securities 16,972 — (69) 16,903 Level 2 Total available-for-sale securities $ 483,605 $ 10 $ (2,413) $ 481,202 As of December 31, 2021, the Company held $548.0 million in money market funds with no unrealized gains or losses and no marketable securities as of this date. The contractual maturities of marketable securities as of March 31, 2022 were as follows (in thousands): Amortized Cost Fair Value Due in one year or less $ 63,029 $ 62,706 Due after one year to five years 166,210 164,130 Total marketable securities $ 229,239 $ 226,836 Inventory Inventory was comprised of the following (in thousands): March 31, December 31, Purchased materials $ 33,905 $ 31,954 Work in progress 15,070 14,052 Finished goods 14,722 13,960 Inventory $ 63,697 $ 59,966 Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued payroll and related costs $ 3,152 $ 3,978 Employee stock purchase program liability 3,891 1,693 Accrued bonus 5,308 16,558 Accrued commissions 2,828 3,417 Accrued acquisition-related compensation 1,060 4,430 Accrued vacation 1,209 1,172 Other 876 378 Accrued compensation and related benefits $ 18,324 $ 31,626 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued legal and related costs $ 2,930 $ 2,425 Accrued license fee 5,901 6,214 Accrued royalties for licensed technologies 4,027 4,415 Accrued property and equipment 14,677 15,361 Accrued professional services 5,187 8,593 Product warranties 1,097 994 Customer deposits 826 954 Taxes payable 1,905 4,622 Accrued lab supplies 1,230 2,056 Other 6,315 5,275 Accrued expenses and other current liabilities $ 44,095 $ 50,909 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Three Months Ended 2022 2021 Beginning of period $ 994 $ 399 Amounts charged to cost of revenue 775 591 Repairs and replacements (672) (538) End of period $ 1,097 $ 452 Revenue and Deferred Revenue As of March 31, 2022, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of Chromium instruments, was $7.9 million, of which approximately $5.4 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $7.9 million and $7.7 million as of March 31, 2022 and December 31, 2021, respectively, consisted of deferred revenue related to extended warranty service agreements. Revenue recorded during the three months ended March 31, 2022 included $1.6 million of previously deferred revenue that was included in contract liabilities as of December 31, 2021. The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended 2022 2021 Instruments $ 14,429 $ 11,125 Consumables 97,950 93,079 Services 2,117 1,617 Total revenue $ 114,496 $ 105,821 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended 2022 2021 United States $ 57,441 $ 50,306 Europe, Middle East and Africa 20,532 19,170 China 20,760 23,640 Asia-Pacific (excluding China) 13,517 11,204 North America (excluding United States) 2,246 1,501 Total revenue $ 114,496 $ 105,821

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements On November 6, 2020, the Company entered into a Master Lease Agreement ("MLA") to lease additional office building space near the Company's Pleasanton, California headquarters. The MLA consists of various lease components, a few of which commenced in the three months ended March 31, 2022. The sole outstanding component is expected to commence in 2023 and is expected to terminate on June 30, 2033. Total undiscounted payments for the lease component commencing in fiscal year 2023 will be $14.0 million with an expected lease term of 10.5 years. Future net lease payments related to the Company’s operating lease liabilities as of March 31, 2022 is as follows (in thousands): Operating Leases 2022 (excluding the three months ended March 31, 2022) $ 8,678 2023 15,078 2024 15,217 2025 14,051 2026 14,806 Thereafter 61,867 Total lease payments $ 129,697 Less: imputed interest (28,522) Present value of operating lease liabilities $ 101,175 Operating lease liabilities, current $ 7,637 Operating lease liabilities, noncurrent $ 93,538 The following table summarizes additional information related to operating leases as of March 31, 2022: March 31, December 31, 2021 Weighted-average remaining lease term 8.7 years 8.7 years Weighted-average discount rate 5.5 % 5.4 % Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. Nanostring On May 6, 2021, the Company filed suit against Nanostring Technologies, Inc. ("Nanostring") in the U.S. District Court for the District of Delaware alleging that Nanostring's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219. On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. Discovery is in progress. A Markman hearing is scheduled for October 2022 and trial is scheduled for June 2023. On February 28, 2022, the Company filed a second suit against Nanostring in the U.S. District Court for the District of Delaware alleging that Nanostring's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737, which are exclusively licensed to the Company from Harvard University. Nanostring filed its answer on April 21, 2022. No case schedule has been entered and discovery has not yet commenced. On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that Nanostring's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1. Nanostring has not yet responded to the complaint. Vizgen In May 2022, the Company filed suit against Vizgen, Inc. ("Vizgen") in the U.S. District Court for the District of Delaware alleging that Vizgen’s MERSCOPE Platform and workflow and Vizgen’s Lab Services program, including associated instruments and reagents, infringe U.S. Patent Nos. 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,299,767, which are exclusively licensed to the Company from Harvard University. Vizgen has not yet responded to the complaint. For further discussion of the risks relating to intellectual property and our pending litigation, see the section titled “ Risk Factors—Risks related to litigation and our intellectual property ” under Item 1A below.

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Capital Stock	Capital StockAs of March 31, 2022, the number of shares of Class A common stock and Class B common stock issued and outstanding were 93,829,885 and 19,446,465, respectively. During the three months ended March 31, 2022 and 2021, 200,000 and 150,000 shares of Class B common stock, respectively, were converted to shares of Class A common stock upon the election of the holders of such shares.

Equity Incentive Plans

Equity Incentive Plans	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans 2019 Employee Stock Purchase Plan A total of 3,284,859 shares of Class A common stock was reserved for issuance under the 2019 Employee Stock Purchase Plan ("ESPP"). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. Shares purchased under the ESPP are subject to a one-year holding period following the purchase date. During the three months ended March 31, 2022 and 2021, no shares of Class A common stocks were issued under the ESPP. As of March 31, 2022, there were 3,057,556 shares available for issuance in connection under the ESPP. Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended 2022 2021 Cost of revenue $ 1,014 $ 464 Research and development 11,291 6,796 Selling, general and administrative 13,742 8,916 Total stock-based compensation expense $ 26,047 $ 16,176 Restricted Stock Units Restricted stock unit activity for the three months ended March 31, 2022 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2021 1,298,244 $ 141.48 Granted 517,650 82.28 Vested (109,196) 135.86 Cancelled (96,307) 118.30 Outstanding as of March 31, 2022 1,610,391 $ 124.21 Stock Options Stock option activity for the three months ended March 31, 2022 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2021 8,212,754 $ 29.28 Granted 944,754 70.53 Exercised (652,177) 12.00 Cancelled (85,887) 55.78 Outstanding as of March 31, 2022 8,419,444 $ 34.97

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended 2022 2021 Stock options to purchase common stock 8,419,444 11,054,573 Restricted stock units 1,610,391 985,386 Shares committed under ESPP 60,181 26,271 Shares subject to repurchase 12,500 53,125 Contingent restricted shares — 236,484 Total 10,102,516 12,355,839

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2021 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Marketable Securities	Marketable Securities The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities, within current assets on the balance sheet. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in "Accumulated other comprehensive income (loss)", a component of stockholders’ equity, net of tax. Realized gains (losses) on the sale of marketable securities are determined using the specific-identification method and recorded in "Other expense, net" in the Consolidated Statements of Operations. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in “Other expense, net”, and unrealized losses not related to credit losses are recognized in “Accumulated other comprehensive income (loss)”. There are no allowances for credit losses for the periods presented. As of March 31, 2022, the gross unrealized losses on available-for-sale securities are related to market interest rate changes and not attributable to credit.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Cash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy. Assets recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 - Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s financial instruments consist of Level 1, Level 2 and Level 3 assets. Where quoted prices are available in an active market, securities are classified as Level 1. Money market funds are classified as Level 1. Level 2 assets consist primarily of corporate bonds, asset backed securities, commercial paper, U.S. Government Treasury and agency securities, and debt securities in government-sponsored entities based upon quoted market prices for similar movements in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party data providers, including but not limited to, benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis.

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Marketable Securities	Available-for-sale securities at March 31, 2022 consisted of the following (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Fair Value Measurement Cash equivalents: Money market funds $ 254,366 $ — $ — $ 254,366 Level 1 Marketable securities: Corporate debt securities 158,165 10 (1,817) 156,358 Level 2 Government debt securities 54,102 — (527) 53,575 Level 2 Asset-backed securities 16,972 — (69) 16,903 Level 2 Total available-for-sale securities $ 483,605 $ 10 $ (2,413) $ 481,202
Debt Securities, Available-for-sale	The contractual maturities of marketable securities as of March 31, 2022 were as follows (in thousands): Amortized Cost Fair Value Due in one year or less $ 63,029 $ 62,706 Due after one year to five years 166,210 164,130 Total marketable securities $ 229,239 $ 226,836
Schedule of Inventory	Inventory was comprised of the following (in thousands): March 31, December 31, Purchased materials $ 33,905 $ 31,954 Work in progress 15,070 14,052 Finished goods 14,722 13,960 Inventory $ 63,697 $ 59,966
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued payroll and related costs $ 3,152 $ 3,978 Employee stock purchase program liability 3,891 1,693 Accrued bonus 5,308 16,558 Accrued commissions 2,828 3,417 Accrued acquisition-related compensation 1,060 4,430 Accrued vacation 1,209 1,172 Other 876 378 Accrued compensation and related benefits $ 18,324 $ 31,626
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued legal and related costs $ 2,930 $ 2,425 Accrued license fee 5,901 6,214 Accrued royalties for licensed technologies 4,027 4,415 Accrued property and equipment 14,677 15,361 Accrued professional services 5,187 8,593 Product warranties 1,097 994 Customer deposits 826 954 Taxes payable 1,905 4,622 Accrued lab supplies 1,230 2,056 Other 6,315 5,275 Accrued expenses and other current liabilities $ 44,095 $ 50,909
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Three Months Ended 2022 2021 Beginning of period $ 994 $ 399 Amounts charged to cost of revenue 775 591 Repairs and replacements (672) (538) End of period $ 1,097 $ 452
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended 2022 2021 Instruments $ 14,429 $ 11,125 Consumables 97,950 93,079 Services 2,117 1,617 Total revenue $ 114,496 $ 105,821
Schedule of Revenue by Geographic Location	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended 2022 2021 United States $ 57,441 $ 50,306 Europe, Middle East and Africa 20,532 19,170 China 20,760 23,640 Asia-Pacific (excluding China) 13,517 11,204 North America (excluding United States) 2,246 1,501 Total revenue $ 114,496 $ 105,821

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	Future net lease payments related to the Company’s operating lease liabilities as of March 31, 2022 is as follows (in thousands): Operating Leases 2022 (excluding the three months ended March 31, 2022) $ 8,678 2023 15,078 2024 15,217 2025 14,051 2026 14,806 Thereafter 61,867 Total lease payments $ 129,697 Less: imputed interest (28,522) Present value of operating lease liabilities $ 101,175 Operating lease liabilities, current $ 7,637 Operating lease liabilities, noncurrent $ 93,538
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of March 31, 2022: March 31, December 31, 2021 Weighted-average remaining lease term 8.7 years 8.7 years Weighted-average discount rate 5.5 % 5.4 %

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended 2022 2021 Cost of revenue $ 1,014 $ 464 Research and development 11,291 6,796 Selling, general and administrative 13,742 8,916 Total stock-based compensation expense $ 26,047 $ 16,176
Summary of RSU activity	Restricted stock unit activity for the three months ended March 31, 2022 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2021 1,298,244 $ 141.48 Granted 517,650 82.28 Vested (109,196) 135.86 Cancelled (96,307) 118.30 Outstanding as of March 31, 2022 1,610,391 $ 124.21
Summary of the Company's Stock Option Activity	Stock option activity for the three months ended March 31, 2022 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2021 8,212,754 $ 29.28 Granted 944,754 70.53 Exercised (652,177) 12.00 Cancelled (85,887) 55.78 Outstanding as of March 31, 2022 8,419,444 $ 34.97

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended 2022 2021 Stock options to purchase common stock 8,419,444 11,054,573 Restricted stock units 1,610,391 985,386 Shares committed under ESPP 60,181 26,271 Shares subject to repurchase 12,500 53,125 Contingent restricted shares — 236,484 Total 10,102,516 12,355,839

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Revenue recognition, payment due period	45 days

Other Financial Statement Inf_3

Other Financial Statement Information - Available-for-Sale Securities (Details) $ in Thousands	Mar. 31, 2022USD ($)
Marketable Securities [Line Items]
Total marketable securities	$ 229,239
Gross Unrealized Gains	10
Gross Unrealized Losses	(2,413)
Marketable securities, fair value	226,836
Total available-for-sale securities, amortized cost	483,605
Total available-for-sale securities, fair value	481,202
Money market funds | Level 1
Marketable Securities [Line Items]
Money market funds	254,366
Corporate debt securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	158,165
Gross Unrealized Gains	10
Gross Unrealized Losses	(1,817)
Marketable securities, fair value	156,358
Government debt securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	54,102
Gross Unrealized Gains	0
Gross Unrealized Losses	(527)
Marketable securities, fair value	53,575
Asset-backed securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	16,972
Gross Unrealized Gains	0
Gross Unrealized Losses	(69)
Marketable securities, fair value	$ 16,903

Other Financial Statement Inf_4

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Transaction price allocated to remaining performance obligations	$ 7,900
Deferred revenue	5,434	$ 5,340
Contract liability	7,900	7,700
Contract with customer, liability, revenue recognized	1,600
Money market funds | Level 1
Concentration Risk [Line Items]
Money market funds		$ 548,000
Products and Services, Excluding Grant Revenue
Concentration Risk [Line Items]
Deferred revenue	$ 5,400

Other Financial Statement Inf_5

Other Financial Statement Information - Contractual Maturities of Marketable Securities (Details) $ in Thousands	Mar. 31, 2022USD ($)
Amortized Cost
Due in one year or less	$ 63,029
Due after one year to five years	166,210
Total marketable securities	229,239
Fair Value
Due in one year or less	62,706
Due after one year to five years	164,130
Total marketable securities	$ 226,836

Other Financial Statement Inf_6

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 33,905	$ 31,954
Work in progress	15,070	14,052
Finished goods	14,722	13,960
Inventory	$ 63,697	$ 59,966

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 3,152	$ 3,978
Employee stock purchase program liability	3,891	1,693
Accrued bonus	5,308	16,558
Accrued commissions	2,828	3,417
Accrued acquisition-related compensation	1,060	4,430
Accrued vacation	1,209	1,172
Other	876	378
Accrued compensation and related benefits	$ 18,324	$ 31,626

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal and related costs	$ 2,930	$ 2,425
Accrued license fee	5,901	6,214
Accrued royalties for licensed technologies	4,027	4,415
Accrued property and equipment	14,677	15,361
Accrued professional services	5,187	8,593
Product warranties	1,097	994
Customer deposits	826	954
Taxes payable	1,905	4,622
Accrued lab supplies	1,230	2,056
Other	6,315	5,275
Accrued expenses and other current liabilities	$ 44,095	$ 50,909

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 994	$ 399
Amounts charged to cost of revenue	775	591
Repairs and replacements	(672)	(538)
End of period	$ 1,097	$ 452

Other Financial Statement In_10

Other Financial Statement Information - Revenue Recognition (Details)	Mar. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected period of revenue recognition	12 months

Other Financial Statement In_11

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from External Customer [Line Items]
Revenue	$ 114,496	$ 105,821
Instruments
Revenue from External Customer [Line Items]
Revenue	14,429	11,125
Consumables
Revenue from External Customer [Line Items]
Revenue	97,950	93,079
Services
Revenue from External Customer [Line Items]
Revenue	$ 2,117	$ 1,617

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 114,496	$ 105,821
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	57,441	50,306
Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	20,532	19,170
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	20,760	23,640
Asia-Pacific (excluding China)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	13,517	11,204
North America, Excluding United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 2,246	$ 1,501

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Pleasanton, California $ in Millions	Mar. 31, 2022USD ($)
Loss Contingencies [Line Items]
Lease payment commencing 2023	$ 14
2023
Loss Contingencies [Line Items]
Weighted-average expected lease terms	10 years 6 months

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Detail) $ in Thousands	Mar. 31, 2022USD ($)
Operating Leases
2022 (excluding the three months ended March 31, 2022)	$ 8,678
2023	15,078
2024	15,217
2025	14,051
2026	14,806
Thereafter	61,867
Total lease payments	129,697
Less: imputed interest	(28,522)
Present value of operating lease liabilities	101,175
Operating lease liabilities, current	7,637
Operating lease liabilities, noncurrent	$ 93,538

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term, operating leases	8 years 8 months 12 days	8 years 8 months 12 days
Weighted-average discount rate, operating leases	5.50%	5.40%

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Shares Converted From Class B to Class A
Class of Stock [Line Items]
Conversion of stock, shares converted (in shares)	200,000	150,000
Common Class A
Class of Stock [Line Items]
Common stock shares issued (in shares)	93,829,885
Common stock shares outstanding (in shares)	93,829,885
Common Class B
Class of Stock [Line Items]
Common stock shares issued (in shares)	19,446,465
Common stock shares outstanding (in shares)	19,446,465

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - Common Class A - 2019 Employee Stock Purchase Plan - Employee Stock - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	3,057,556		3,284,859
Share-based compensation arrangement percent	85.00%
Holding period following purchase	1 year
Shares issued in period for previously outstanding awards (in shares)	0	0

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 26,047	$ 16,176
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	1,014	464
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	11,291	6,796
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 13,742	$ 8,916

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of RSU Activity (Detail)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Restricted Stock Units
Restricted Stock Units, Beginning balance (in shares) | shares	1,298,244
Restricted Stock Units, Granted (in shares) | shares	517,650
Restricted Stock Units, Vested (in shares) | shares	(109,196)
Restricted Stock Units, Cancelled (in shares) | shares	(96,307)
Restricted Stock Units, Ending balance (in shares) | shares	1,610,391
Weighted-Average Grant Date Fair Value (per share)
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares	$ 141.48
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	82.28
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	135.86
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	118.30
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares	$ 124.21

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Company's Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Stock Options
Outstanding stock options, Beginning balance (in shares) | shares	8,212,754
Outstanding stock options - Granted (in shares) | shares	944,754
Outstanding stock options - Exercised (in shares) | shares	(652,177)
Outstanding stock options - Cancelled (in shares) | shares	(85,887)
Outstanding stock options, Ending balance (in shares) | shares	8,419,444
Weighted-Average Exercise Price
Weighted-average exercise price - Beginning balance (in dollars per share) | $ / shares	$ 29.28
Weighted-average exercise price - Granted (in dollars per share) | $ / shares	70.53
Weighted-average exercise price - Exercised (in dollars per share) | $ / shares	12
Weighted-average exercise price - Cancelled (in dollars per share) | $ / shares	55.78
Weighted-average exercise price - Ending balance (in dollars per share) | $ / shares	$ 34.97

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	10,102,516	12,355,839
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	8,419,444	11,054,573
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,610,391	985,386
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	60,181	26,271
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	12,500	53,125
Contingent restricted shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	236,484